| Safety and Efficacy of Etanercept in a Cohort of Patients with Juvenile Idiopathic Arthritis Under 4 Years of Age. | |
| | |
MedLine Citation:
|
PMID: 22589254 Owner: NLM Status: Publisher |
Abstract/OtherAbstract:
|
OBJECTIVE: To evaluate safety, tolerability, and efficacy of etanercept in a cohort of patients with juvenile idiopathic arthritis (JIA) under 4 years of age. METHODS: Data were collected at every visit during treatment with etanercept in 25 children who began treatment at a mean age of 3 years (range 18-48 months). Safety endpoints included the incidence of any adverse events. Efficacy endpoints included the American College of Rheumatology (ACR) Pediatric 30, 50, and 70 criteria for improvement. RESULTS: Data from 25 patients with JIA treated with etanercept for a mean period of 23 months were analyzed. All patients received concomitant medications: 24 methotrexate, 3 cyclosporin A, and 10 corticosteroids. After the first 6 months of treatment, 15 (71.4%) patients achieved an ACR Pedi30 response and at the last observation 20 (80%) achieved ACR Pedi30. ACR Pedi50 and 70 responses were, respectively, 62% and 43% at 6 months and 72% and 64% at the last followup. Five patients (20%) discontinued etanercept for lack of efficacy. Two (8%) developed adverse events, both primary varicella zoster virus (VZV) infections (both not vaccinated). One was hospitalized because of a necrotizing fasciitis secondary to VZV infection. No cases of tuberculosis, opportunistic infections, or malignancies were reported. CONCLUSION: In our cohort of patients etanercept proved to be safe and efficacious in the majority of children. The response in toddlers was similar to that in older children. We observed only 1 case of severe infection that required hospitalization and stopped treatment temporarily. |
| | |
Authors:
|
Claudia Bracaglia; Paola S Buonuomo; Alberto E Tozzi; Manuela Pardeo; Rebecca Nicolai; Andrea Campana; Antonella Insalaco; Elisabetta Cortis; Fabrizio De Benedetti |
Related Documents
:
|
22538694 - The linx(®) reflux management system: confirmed safety and efficacy now at 4 years. 22435854 - Prospective evaluation of anticoagulation and transjugular intrahepatic portosistemic s... 19438414 - Outpatient management of primary spontaneous pneumothorax in the emergency department o... 22639434 - Acute and long-term results of carotid stenting under proximal embolic protection using... 6161574 - A continuing medical education program in chronic obstructive pulmonary diseases: desig... 15878484 - Effects of dual therapy with corticosteroids plus long acting beta2-agonists in asthma. |
Publication Detail:
|
Type: JOURNAL ARTICLE Date: 2012-5-15 |
Journal Detail:
|
Title: The Journal of rheumatology Volume: - ISSN: 0315-162X ISO Abbreviation: - Publication Date: 2012 May |
Date Detail:
|
Created Date: 2012-5-16 Completed Date: - Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 7501984 Medline TA: J Rheumatol Country: - |
Other Details:
|
Languages: ENG Pagination: - Citation Subset: - |
Affiliation:
|
From the Division of Rheumatology, Department of Pediatric Medicine; and Division of Epidemiology, Ospedale Pediatrico Bambino Gesù IRCCS, Rome, Italy. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
|
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Autofeedback from ultrasound images provides rapid improvement in palpation skills for identifying j...
Next Document: Treatment with Biologic Agents Improves the Prognosis of Patients with Rheumatoid Arthritis and Amyl...